Thermo Fisher Scientific’s new $5bn buyback: A confidence signal or capital allocation test?
Thermo Fisher Scientific authorises a $5 billion buyback after strong Q3 results. Examine cash flow, acquisitions and shareholder returns.
Pharma & Biotech
Medical Devices & Diagnostics
EQT offers QIAGEN shareholders a 40% premium, but can its €10.8bn diagnostics bet unlock faster growth?
EQT agrees a €10.8 billion takeover of QIAGEN at €46.50 per share. Diagnostics growth, financing and shareholder approval remain key.
Medical Devices & Diagnostics
Why the Perceptive Discovery and Nucleus RadioPharma agreement matters for oncology drug development
Perceptive Discovery and Nucleus RadioPharma link imaging and manufacturing to address critical bottlenecks in radiopharmaceutical development.
Medical Devices & Diagnostics
Thermo Fisher Scientific expands specialty diagnostics strategy with EXENT and EliA CTD 13 Screen
Thermo Fisher’s ADLM 2026 showcase links new diagnostics, lab quality tools and workflow scale, while active device corrections test execution.
Pharma & Biotech
Why Thermo Fisher Scientific’s ASMS 2026 launch matters for drug discovery workflows
Thermo Fisher Scientific unveils new Orbitrap platforms at ASMS 2026. Find out how they could reshape drug discovery workflows today!
Pharma & Biotech
Why Thermo Fisher’s new Gothenburg lab matters for the next phase of complex drug development
Complex therapies need deeper trial data. Thermo Fisher’s Gothenburg lab shows why bioanalysis is becoming a CRO battleground.
Pharma & Biotech
Can Thermo Fisher help Nuvation Bio scale Ibtrozi supply for ROS1-positive NSCLC?
Rare cancer drugs need more than FDA approval. Nuvation Bio’s Ibtrozi test now shifts to U.S. supply reliability and launch execution.
Medical Devices & Diagnostics
Faster Candida auris identification? Thermo Fisher Scientific unveils new agar
Thermo Fisher Scientific launches chromogenic media to detect Candida auris faster. Explore what this means for labs and AMR strategy.